VTRS
Viatris IncPrice
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Mar 23 ▼ 1 insider sell $283.5K at $13.28
- May 27 ▼ Ro Khanna sold $1,001 - $15,000, last disclosed Jun 11
- Jun 25 ▼ 1 insider sell $809.8K at $16.17
- Aug 3 LU v. VIATRIS SPECIALTY, LLC d/b/a VIATRIS MEDICAL UNIT
- Aug 6 ▲ Viatris Q2 2026 earnings beat consensus with adjusted EPS of $0.69 (…
- Sep 23 Oppenheimer initiates
- Sep 30 ▲ 3 funds open new positions (13F)
- Oct 8 ▲ Viatris (VTRS) has agreed to acquire Pacira BioSciences (PCRX) for $…
- Oct 16 ▲ Viatris received FDA approval for RYZUMVI (phentolamine ophthalmic s…
- Oct 30 ▲ Viatris has commenced a tender offer to acquire all outstanding shar…
- Nov 4 Dividend: Viatris Announces Quarterly Dividend
- Nov 5 Viatris reported Q3 2026 total revenues of $3.75B, essentially flat…
- Nov 17 New catalyst: subscribers see the details Unlock
Signal stack
Where each data set points today.
- InsidersBEARISH
1 insider sold $1.1M.
- InstitutionsBULLISH
Q3 2026: 55 added (3 new), 24 trimmed or exited. Largest new: Sound Shore Management /Ct/ $81.3M.
- AnalystsBULLISH
12 of 18 rate it Buy or better.
- Short sellersSTEADY
Short interest −7.1% to 35.24M shares. 4.0 days to cover, ≈3.1% of shares.
- TrendUPTREND
12% above its 50-day average. New closing high $21.06 on Nov 11.
- SocialQUIET
No Reddit mentions this week. Last mention Oct 30.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| FMR LLC | ADD | $2.4B |
| DIMENSIONAL FUND ADVISORS LP | TRIM | $304.9M |
| Assenagon Asset Management S.A. | DOUBLED | $186.7M |
| CITIGROUP INC | ADD | $108.8M |
| SOUND SHORE MANAGEMENT INC /CT/ | NEW | $81.3M |
| VICTORY CAPITAL MANAGEMENT INC | ADD | $71.4M |
| Qube Research & Technologies Ltd | TRIM | $66.5M |
| FIRST TRUST ADVISORS LP | DOUBLED | $64.5M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
18 analysts| Date | Firm | Rating |
|---|---|---|
| Nov 17, 2026 | 🔒 Fresh data, subscribers only MAINTAIN | |
| Nov 16, 2026 | Barclays MAINTAIN | Overweight |
| Nov 6, 2026 | JP Morgan MAINTAIN | Neutral |
| Oct 26, 2026 | Piper Sandler MAINTAIN | Neutral |
| Oct 21, 2026 | JP Morgan MAINTAIN | Neutral |
| Oct 5, 2026 | UBS MAINTAIN | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
SIMMONS DAVID S Director Sep 30, 2026 | AWARD | $37.5K |
Groothuis Leo Frans Director Sep 30, 2026 | AWARD | $43.8K |
Enrietti Andrew See Remarks Aug 15, 2026 | EXERCISE | 25,134 sh |
Enrietti Andrew See Remarks Aug 15, 2026 | EXERCISE | 999 sh |
Enrietti Andrew See Remarks Aug 15, 2026 | EXERCISE | 998.364 sh |
Enrietti Andrew See Remarks Aug 15, 2026 | TAX W/H | $7.1K |
Enrietti Andrew See Remarks Aug 15, 2026 | TAX W/H | $177.4K |
Groothuis Leo Frans Director Jun 30, 2026 | AWARD | $43.8K |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Washington
Short side
FINRA· Oct 30, 2026SecBot reports
18 filings · 4 press releases · 6 bullish · 1 bearish · 3 mixed · 8 neutral- NEUTRAL 8-KNov 17, 2026
Viatris completed its acquisition of Pacira BioSciences for $36.50 per share in cash, with an aggregate deal value of approximately $1.69 billion. The tender offer received 66.46% of Pacira shares, and the remaining shares were acquired via a merger under Section 251(h) of the DGCL.
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL PRESS RELEASENov 17, 2026
Viatris completed its acquisition of Pacira BioSciences for $36.50 per share in cash, with approximately 32,929,780 shares (66.46% of outstanding) tendered and accepted. The merger closed via Section 251(h) without a Pacira stockholder vote, and Pacira shares will be delisted from Nasdaq.
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL SC 13G/ANov 16, 2026
T. Rowe Price Associates filed an amended Schedule 13G disclosing a 5.1% passive stake in Viatris…
The reduction is modest and routine for a passive manager; no change in investment thesis is signaled. Monitor future 13G filings to see if the trend continues toward the 5% threshold.
- NEUTRAL SC 13G/ANov 6, 2026
Davis Selected Advisers filed an amended Schedule 13G disclosing a 6.3% passive stake in Viatris…
The incremental increase is routine for a passive manager. Monitor the next 13F filing for any change in Davis Selected Advisers' position size relative to this disclosure.
All VTRS filing & press-release reports (22)
- 8-K reportNov 17, 2026
- PRESS-RELEASE reportNov 17, 2026
- SC 13G/A reportNov 16, 2026
- SC 13G/A reportNov 6, 2026
- 8-K reportNov 5, 2026
- PRESS-RELEASE reportNov 4, 2026
- PRESS-RELEASE reportOct 30, 2026
- INST-CLUSTER reportOct 29, 2026
- PRESS-RELEASE reportOct 16, 2026
- 8-K reportOct 8, 2026
- 8-K reportAug 6, 2026
- COURT-RULING reportMay 4, 2026
- COURT-RULING reportMay 4, 2026
- COURT-RULING reportApr 13, 2026
- COURT-RULING reportApr 13, 2026
- 144 reportJun 25, 2026
- 8-K reportJun 18, 2026
- 8-K reportJun 15, 2026
- COURT-RULING reportMay 13, 2026
- 8-K reportMay 7, 2026
- 8-K reportMay 4, 2026
- 8-K reportFeb 26, 2026